How do you approach using non-anthracycline based neoadjuvant treatment for triple negative breast cancer, especially in older patients with node negative disease?

There is compelling data that including carboplatin in neoadjuvant therapy for TNBC significantly increases pCR rates, and may allow omission of an anthracycline without compromising long-term outcomes. Until very recently, my anthracycline-free neoadjuvant regimen of choice was every 3-weeks doceta...